
Opinion|Videos|March 4, 2024
Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer
A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
2
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
3
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
4
Efgartigimod Outperforms Standard IVIG in Averting Myasthenic Crisis
5